Mergers & Acquisitions - Mergers & Acquisitions, Novartis

Filter

Popular Filters

FTC puts conditions on Eli Lilly’s proposed acquisition of Novartis Animal Health

23-12-2014

US pharma major Eli Lilly has agreed to divest its Sentinel product line of medications for treating…

Eli LillyMergers & AcquisitionsNovartisPharmaceuticalUSA

FTC puts conditions on GSK/Novartis consumer JV

27-11-2014

The US Federal Trade Commission has voted to approve UK pharma giant GlaxoSmithKline’s proposed acquisition…

Dr Reddy's LaboratoriesGlaxoSmithKlineHabitrolMergers & AcquisitionsNicodermNovartisPharmaceuticalRegulationUSAVaccines

Global oncology market to hit $109 billion in 2020

Global oncology market to hit $109 billion in 2020

26-11-2014

Cancer, with a death toll exceeding that of AIDS (acquired immune deficiency syndrome), tuberculosis…

AvastinCelgene Corp.GlobalMarkets & MarketingMergers & AcquisitionsNovartisOncologyPharmaceuticalResearchRevlimidRoche

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

MorphoSys gets milestone from Novartis; acquires new technology

21-10-2014

German company MorphoSys says it has received a milestone payment from Novartis in connection with the…

BiotechnologyLanthio PharmalanthipeptideMergers & AcquisitionsMorphoSysNovartisOphthalmicsResearch

Oxford BioMedica enters LentiVector collaboration with Novartis

Oxford BioMedica enters LentiVector collaboration with Novartis

10-10-2014

UK-based Oxford BioMedica says that it has signed further contracts with Swiss pharma giant Novartis,…

GlobalLentiVectorLicensingMergers & AcquisitionsNovartisOncologyOxford BioMedicaPharmaceutical

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

22-04-2014

In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

31-03-2014

Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

Novartis sells blood transfusion diagnostics unit to Grifols for $1.675 billion

Novartis sells blood transfusion diagnostics unit to Grifols for $1.675 billion

11-11-2013

Swiss drug major Novartis says it is divesting its blood transfusion diagnostics unit to Spain’s Grifols…

GrifolsMergers & AcquisitionsNovartisPharmaceutical

Clinigen acquires oncology support therapy Cardioxane from Novartis

26-03-2013

UK-based Clinigen Group (LSE: CLIN) says it has acquired (AIM: CLIN) the oncology support therapy Cardioxane…

CardioxaneClinigen GroupGlobalMergers & AcquisitionsNovartisOncologyPharmaceutical

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis

21-12-2012

French drug major Sanofi (Euronext: SAN) has entered into a binding agreement to acquire the animal health…

BayerDosch PharmaceuticalsExjadeFlonaseGlaxoSmithKlineLegalMergers & AcquisitionsMerialNovartisOncologyPharmaceuticalregorafenibRegulationRespiratory and PulmonarySanofi

Validus Pharma gets rights to six Novartis drugs in USA

19-11-2012

USA-based Validus Pharmaceuticals (NYSE: VR) together with Wood Creek Capital Management, have acquired…

GenericsMergers & AcquisitionsNovartisValidus Pharma

US FTC puts divestment conditions on Watson's acquisition of Actavis

16-10-2012

The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic…

ActavisGenericsLegalMergers & AcquisitionsNorth AmericaNovartisPar PharmaceuticalsSandozWatson Pharmaceuticals

News briefs: Drug majors eyeing Strides Arcolab unit; Astellas invests in oncology facility

20-08-2012

Leading drug multinationals, including global behemoth Pfizer (NYSE: PFE) and Swiss major Novartis (NOVN:…

Agila SpecialitesAstellas PharmaGenericsHospiraMergers & AcquisitionsNovartisPfizerPharmaceuticalProductionStrides Arcolab

US FTC puts conditions on Novartis buy of Fougera

17-07-2012

The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalTolmar

Novartis to buy US generic derma company Fougera for over $1.5 billion

03-05-2012

Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNovartisPharmaceuticalSandoz

Cushing’s syndrome patients to receive safer drug options

22-02-2012

New upcoming treatments for Cushing’s syndrome promise to improve patient’s quality of life,…

Corcept TherapeuticsHRA PharmaKorlymMergers & AcquisitionsMifedrenNovartisPharmaceuticalRare diseasesResearchSignifor

Back to top